title: Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats.
abstract: Hematic administration of bone marrow-derived mesenchymal stem cells (MSCs) in acute ischemic stroke may not only be an effective reparative treatment but also a brain protective therapy that improves neurological recovery. Our purpose was to study whether either i.v. or intracarotid (i.c.) administration of allogenic MSCs during the acute phase were effective in improving neurological recovery and decreasing brain damage in an experimental rat model. In a model of permanent middle cerebral artery occlusion (pMCAO), we analyzed: neurological evaluation; MSCs migration and implantation; interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels; lesion volume; cell death; cellular proliferation; vascular endothelial growth factor (VEGF) expression and blood vessel number. Regardless of the administration route, treated groups showed better neurological recovery, without significant differences between the two groups. Migration and implantation of MSCs in the lesion area was observed in animals receiving i.c. but not i.v. treatment. The highest cytokine values were observed in the i.v. MSCs and i.c. control groups, and these levels were significantly different from the corresponding i.v. control and i.c. MSCs groups, respectively. In addition, there were significant differences between the i.v. MSCs and i.c. MSCs groups in IL-6 levels. Neither treatment reduced infarction volume. However, cell death, measured as TUNEL+ cells was decreased with significant differences between control groups. BrdU+ cells were also significantly increased in the peri-infarct zone at 14 days. VEGF expression was significantly higher in the i.c. MSCs group than in the i.c. control group and blood vessel number was significantly higher in treated groups than control groups with significant differences in the peri-infarct zone at 14 days. We conclude that allogenic MSCs administration shows therapeutic efficacy in our acute ischemic stroke model. Both routes demonstrably improved neurological recovery and provided brain protection.
authors.affiliation: Hospital La Paz/Autonoma University School of Medicine, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Gutiérrez-Fernández
authors.forename: B
authors.initials: B
authors.lastname: Rodríguez-Frutos
authors.forename: J
authors.initials: J
authors.lastname: Alvarez-Grech
authors.forename: M T
authors.initials: MT
authors.lastname: Vallejo-Cremades
authors.forename: M
authors.initials: M
authors.lastname: Expósito-Alcaide
authors.forename: J
authors.initials: J
authors.lastname: Merino
authors.forename: J M
authors.initials: JM
authors.lastname: Roda
authors.forename: E
authors.initials: E
authors.lastname: Díez-Tejedor
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D002343:Carotid Artery, Internal; D002478:Cells, Cultured; D004195:Disease Models, Animal; D005260:Female; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000502:physiology*; D020521:Stroke / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D014184:Transplantation, Homologous / Q000379:methods